| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 05/10/2001 | WO2001032648A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 05/10/2001 | WO2001032621A1 Novel indole derivatives and drugs containing the same as the active ingredient |
| 05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032208A1 Adjuvanted genetic vaccines |
| 05/10/2001 | WO2001032207A1 Methods for conferring active/passive immunotherapy |
| 05/10/2001 | WO2001032204A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | WO2001032192A1 Active substance in ganoderma lucidum extract and drugs, health foods and cosmetics containing the same |
| 05/10/2001 | WO2001032189A1 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 05/10/2001 | WO2001032175A1 Isoxazole derivatives to be used as phosphodiesterase vii inhibitors |
| 05/10/2001 | WO2001032169A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032159A2 Methods and formulations for the treatment of infectious bursal disease in avian subjects |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032154A2 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032128A2 Human chemokine beta-13 |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2000064488A3 Somatic transgene immunization and related methods |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389686A1 Adjuvanted genetic vaccines |
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2387808A1 Human chemokine beta-13 |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387620A1 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386938A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385928A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097934A1 Lk6-a derivatives |
| 05/09/2001 | EP1097712A1 Steroid-containing cataplasms and process for producing the same |
| 05/09/2001 | EP1097711A2 Treatment of pulmonary hypertension |
| 05/09/2001 | EP1097241A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 05/09/2001 | EP1097210A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 05/09/2001 | EP1097203A1 Human presenilin-associated protein |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097159A1 Phosphinous and phosphonic acid derivatives used as medicaments |
| 05/09/2001 | EP1097148A2 Polymorph of ritonavir |
| 05/09/2001 | EP1097142A1 Phthalazine derivatives phosphodiesterase 4 inhibitors |
| 05/09/2001 | EP1096954A2 Adjuvant and vaccine compositions containing monophosphoryl lipid a |
| 05/09/2001 | EP1096953A1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 05/09/2001 | EP1096938A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide |
| 05/09/2001 | EP1096928A1 New pharmaceutical preparation and method |
| 05/09/2001 | EP0633776B1 Compounds useful for treating allergic and inflammatory diseases |
| 05/09/2001 | CN1294632A Compsns. derived from i(mycobacterium vaccae) and methods for their use |
| 05/09/2001 | CN1294590A Method of 3-substituted adenines via 2-thioxanthines |
| 05/09/2001 | CN1294580A Indole derivatives with antiviral activity |
| 05/09/2001 | CN1294517A Immunoglobulin molecules having synthetic variable region and modified specificity |
| 05/09/2001 | CN1294511A Medicinal compsns. |
| 05/09/2001 | CN1294196A Immune stimulated holoside substance of bacterial strain from wood layer hole strain and its application |
| 05/09/2001 | CN1065428C Matrix type patch preparations |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |
| 05/08/2001 | US6229013 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 05/08/2001 | US6228991 Amino acid sequence; diagnosis, treatment or prevention of reproductive, developmental, neoplastic, and immunological/ autoimmune disorders; anticarcinogenic agents; antitumor/antiarthrtic/antidiabetic agents; endometriosis |
| 05/08/2001 | US6228987 Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| 05/08/2001 | US6228890 Use of alicyclic diamines as immunomodulators |
| 05/08/2001 | US6228859 Antiasthmatic, antiinflammatory, antiallergen and antidepressant agents |
| 05/08/2001 | US6228847 Inhibitors of nucleoside metabolism |
| 05/08/2001 | US6228838 Bactericide or antibiotic screening; genetic engineering |
| 05/08/2001 | US6228835 Decorin binding protein compositions |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/08/2001 | US6228374 Polypeptides and immunology |
| 05/08/2001 | US6228373 Peptide dimer, glycine, cystine or prolne amino acid for immunology |
| 05/08/2001 | US6228369 Dna sequence codes, tat protein of hiv virus, rev protein and codes, glutamine residues |
| 05/08/2001 | US6228363 Peptides for the treatment of systemic lupus erythematosus |
| 05/08/2001 | US6228359 Treatment of autoimmune diseases by removal of cells and inhibitors |
| 05/08/2001 | US6227195 Coarse spray delivery of functional biologic material |
| 05/08/2001 | CA2066661C Viral vaccine conjugates |
| 05/08/2001 | CA2029694C Heteroatoms-containing tricyclic compounds |
| 05/03/2001 | WO2001031046A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001031008A2 Human and rat fgf-20 genes and gene expression products |
| 05/03/2001 | WO2001031007A2 Nucleic acid molecules derived from rat brain and programmed cell death models |